Brainomix 360 e-CTA vs Pixyl.Neuro

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Brainomix 360 e-CTA
by Brainomix Limited
VS
Pixyl.Neuro
by Pixyl

AI Verdict

Brainomix 360 e-CTA focuses on acute stroke, specifically analyzing CT angiography scans for large vessel occlusions and collateral assessment. Pixyl.Neuro, on the other hand, is designed for detecting and monitoring brain anomalies on MR images for neuroinflammatory and neurodegenerative disorders, including quantitative lesion burden analysis and longitudinal tracking. While both are neurology and radiology AI tools, their primary applications and imaging modalities differ, making them adjacent rather than direct competitors, though Brainomix does distribute Pixyl's Neuro.MS solution in some regions.

Choose Brainomix 360 e-CTA if…

Choose Brainomix 360 e-CTA if you need rapid, AI-powered analysis of CT angiography scans for acute stroke patients. It excels at automating collateral assessment, detecting large vessel occlusions (LVOs), and providing quick insights to support urgent treatment decisions like thrombectomy. This tool is ideal for emergency medicine and stroke teams requiring fast, objective data to streamline the acute stroke pathway and improve communication across a stroke network.

View Brainomix 360 e-CTA →

Choose Pixyl.Neuro if…

Choose Pixyl.Neuro if you require an AI tool for the detection and longitudinal monitoring of brain anomalies in neuroinflammatory and neurodegenerative disorders using MR images. It is particularly well-suited for tracking changes in lesion burden and brain atrophy over time, aiding in the diagnosis and management of conditions such as multiple sclerosis and Alzheimer's disease. This tool provides quantitative reports and annotated DICOMs, making it valuable for neurology and radiology specialists focused on long-term patient care and disease progression.

View Pixyl.Neuro →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Brainomix 360 e-CTA Pixyl.Neuro
Pricing Contact vendor Subscription
Deployment Cloud service (EU and US) and on-site server within the hospital network. Available directly from Pixyl, or via OEM, PACS, and AI platforms.
BAA Available Unknown Yes AI-estimated
FDA Status 1 AI-estimated 1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Brainomix 360 e-CTA

Brainomix 360 e-CTA offers a mobile app for quick, secure access to results, messaging, and calling, which can significantly optimize workflow and facilitate faster treatment decisions in acute stroke settings. It also integrates with existing enterprise directories and supports multi-factor authentication, simplifying user management. Pixyl.Neuro also integrates into existing systems and workflows and provides results within minutes, but lacks explicit mention of a dedicated mobile app for comprehensive communication and workflow optimization.

Clinical Value

Brainomix 360 e-CTA

Brainomix 360 e-CTA is specifically designed for acute stroke patients, providing automated collateral assessment, LVO detection, and CTA acquisition phase indication, which are critical for timely and precise treatment decisions in a time-sensitive condition. It has demonstrated rapid and reliable analysis in real-world settings, with studies showing processing in an average of 4 minutes and high accuracy for LVO detection. While Pixyl.Neuro offers valuable insights for neuroinflammatory and neurodegenerative disorders, its focus is on detection and monitoring of brain anomalies and changes on MR images, which is generally less time-critical than acute stroke intervention.

Pricing & Value

Tie

Both tools require contacting the vendor for specific pricing details, making a direct comparison of cost-effectiveness difficult. Brainomix 360 e-CTA offers individual modules or package licensing, which could provide flexibility. Pixyl.Neuro's pricing is based on the number of analyses and installations. Without transparent pricing, it's challenging to determine which offers better value.

Enterprise Readiness

Brainomix 360 e-CTA

Brainomix 360 e-CTA offers flexible deployment options including cloud service (EU and US) and on-site server, and integrates with existing enterprise directories, LDAP, Microsoft AD, and Single Sign-On, with multi-factor authentication. It also explicitly mentions adherence to GDPR and implied HIPAA compliance. Pixyl.Neuro is also HIPAA and GDPR compliant and can be deployed directly from Pixyl, or via OEM, PACS, and AI platforms, but Brainomix's detailed enterprise integration features suggest a more robust readiness for large-scale deployments.

Innovation

Tie

Both tools demonstrate innovation within their respective neurological domains. Brainomix 360 e-CTA's automated collateral assessment and LVO detection for acute stroke are crucial innovations for a time-sensitive condition. Pixyl.Neuro's use of advanced AI to detect and monitor subtle brain anomalies and track longitudinal changes for neuroinflammatory and neurodegenerative disorders also represents significant innovation in long-term patient management.

Support & Docs

Brainomix 360 e-CTA

Brainomix provides user manuals and documentation for all modules and languages, along with FAQs and direct contact options for support. Pixyl also offers customer support and mentions a user portal, but the breadth and accessibility of documentation appear more comprehensively detailed for Brainomix.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Brainomix 360 e-CTA Pixyl.Neuro
Name Brainomix 360 e-CTA Pixyl.Neuro
Company Brainomix Limited Pixyl
Description AI-powered module within the Brainomix 360 Stroke platform that automates and standardizes the assessment of collaterals and detects large vessel occlusions on CT angiography scans for acute stroke patients. FDA-cleared AI tool that detects and monitors brain anomalies and changes on MR images for neuroinflammatory and neurodegenerative disorders.
Key Features Automated collateral assessment on CTA scans, Computation of CTA Collateral Score (CTA-CS), Automatic Large Vessel Occlusion (LVO) detection, Indication of CTA acquisition phase for quality control, Multi-planar reconstructions (MPRs) with coronal, sagittal, and axial viewing, Integration within Brainomix 360 Stroke platform, DICOM results sent automatically to PACS or other radiology systems, Email result notifications Automated lesion detection and segmentation, Quantitative lesion burden analysis, Longitudinal change tracking, Standardized reporting, Integration with PACS systems, Support for neuroinflammatory disorders (e.g., MS), Support for neurodegenerative disorders (e.g., Alzheimer's), AI-powered image analysis

Videos

Demos, reviews, and walkthroughs featuring Brainomix 360 e-CTA and Pixyl.Neuro.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Brainomix 360 e-CTA is designed to fit into existing workflows, automatically sending DICOM results to PACS or other radiology systems and providing email notifications. It can also deliver results via a mobile app or web UI. Pixyl.Neuro integrates seamlessly into existing systems and workflows, requiring only a single conventional MRI, and can be obtained directly from Pixyl, or via OEM, PACS, and AI platforms. It returns results as PDF reports, annotated DICOMs, and co-registered prior scans, and in routine clinical practice, images can be retrieved automatically from PACS and results returned directly to the hospital PACS as DICOM overlays and structured reports.
For Brainomix 360 e-CTA, a real-world study showed a sensitivity of 0.78 and specificity of 0.93 for LVO detection, with a positive predictive value of 0.5 and a negative predictive value of 0.98. Another study reported a sensitivity of 0.86 and specificity of 0.88 for intracranial proximal LVOs, with a positive predictive value of 0.35 and a negative predictive value of 0.99. For Pixyl.Neuro.MS, a study on detecting new T2/FLAIR lesions in multiple sclerosis patients reported 100% sensitivity for both readers but produced 61 false positives. Pixyl.Neuro has also demonstrated enhanced detection rates up to 28% for brain MRI analysis.
Brainomix 360 Stroke, which includes the e-CTA module, is generally seen as straightforward to use. The technology is perceived as a useful clinical decision support tool, and most clinicians opt to continue using the software with use increasing over time, despite some initial concerns with accuracy. Pixyl.Neuro is designed to integrate seamlessly into existing workflows, and its automated analysis aims to accelerate MRI reading time.
Brainomix provides comprehensive support, which has been recognized as robust and high quality. They offer FAQs, user manuals, and contact information for their team. Pixyl offers customer support, and access to their user portal is protected with whitelisted IP addresses.
For Brainomix 360 Stroke, implementing the software at a network level, rather than individual sites, is recommended to ensure effective adoption. Brainomix 360 Vantage provides real-time visibility on how the platform is performing across a network, allowing monitoring of outcomes, clinician engagement, and operational inefficiencies. Pixyl.Neuro is used in over 12 countries across Europe, North America, and Africa, indicating its suitability for multi-site deployment.
Brainomix 360 Stroke is described as a secure AI imaging solution. Pixyl.Neuro is HIPAA and GDPR compliant, certified for secure healthcare-data hosting (HDS compliant), and its user portal access is protected with whitelisted IP addresses.
Brainomix 360 e-CTA is specifically designed for acute stroke patients, automating and standardizing the assessment of collaterals and detecting large vessel occlusions on CT angiography scans. It aims to support faster, more confident treatment decisions in the acute stroke pathway, including identifying thrombectomy candidates. Pixyl.Neuro is an AI tool for detecting and monitoring brain anomalies and changes on MR images for neuroinflammatory and neurodegenerative disorders, such as Multiple Sclerosis and Alzheimer's Disease. It provides quantitative lesion burden analysis, longitudinal change tracking, and brain volumetry to support diagnosis and monitoring of these conditions.

More Comparisons

eCARTv5 Clinical Deterioration Suite (“eCART”) vs Google Med-PaLM 2
ChatGPT vs Google Med-PaLM 2
When choosing between ChatGPT and Google Med-PaLM 2, physicians should consider their primary use case and desired level of medical…
Brainomix 360 e-CTA vs Google Med-PaLM 2
DeepXray vs Google Med-PaLM 2

More matchups featuring Brainomix 360 e-CTA or Pixyl.Neuro

Backers

Who funded each tool's parent company.

Brainomix 360 e-CTA

AI Tool Finder
AI-powered search. Results may not be comprehensive.